SOURCE: iiBIG

iiBIG

December 14, 2010 10:00 ET

Pharma and Biotech Licensing, Partnering Strategies and Opportunities Covered at iiBIG's March 2011 San Diego Summit

PORT WASHINGTON, NY--(Marketwire - December 14, 2010) - iiBIG presents the Pharma & Biotech Licensing & Partnering conference, scheduled for March 3-4, 2011 at the Doubletree Hotel San Diego Downtown in San Diego, CA. This forum is designed to address the latest strategies, opportunities, and challenges in licensing, business development, strategic alliances and partnerships within the pharmaceutical and biotechnology industries.

With decreasing research and development productivity, continued healthcare cost limitations and the threat of generic competition, only those companies who use the strength of internal efforts combined with successful licensing strategies will remain competitive over the next five-to-ten years. Licensing plays an increasing role in the business model of today's pharmaceutical and biotechnology companies. Licensing options allow for companies to build upon each other's strengths and for deal terms to be structured to balance assurance and reduce risk.

Key issues to be addressed include:

  • What are the best practice strategies in developing an effective win-win licensing deal?
  • Early versus Late Stage Partnering Opportunities
  • Role of Corporate Investors in Today's Deals
  • The Evolving Business Model of Building a Biotech
  • What Uncertain Financial Markets Mean for Deal-Making
  • Maximizing Your Company Value Through Non-Traditional Alliances

Hear from representatives of large, medium, and small pharmaceutical as well as biotechnology companies as they share their insights on the evolving state of the industry: 3M Drug Delivery Systems; Adolor Corporation; Afraxis, Inc.; Altea Therapeutics Corporation; Aradigm Corporation; Arena Pharmaceuticals; Avalon Ventures; Centocor R&D, Inc. (Johnson & Johnson); Eisai Inc.; Elan Drug Technologies; Eurand Pharmaceutical Technologies; Exelixis; Halozyme Therapeutics, Inc.; Johnson & Johnson; Lilly Ventures; MacroGenics, Inc.; MannKind Corporation; Merck & Co.; NAEJA Pharmaceutical Inc.; Novartis Pharmaceuticals; Pfizer; Pfizer Venture Investments; Poniard Pharmaceuticals; Prosensa Therapeutics; Purdue Pharma; Ranbaxy Laboratories Limited; Santarus, Inc.; Shire Pharmaceuticals; Somnus Therapeutics, Inc.; Sun Pharmaceuticals; Supernus Pharmaceuticals, Inc.; The Pfizer Incubator; TheraKine Limited; and ZS Associates.

Conference sponsors include 3M Drug Delivery Systems, Elan Drug Technologies, Eurand Pharmaceutical Technologies, and ZS Associates.

For complete information about this event visit: http://www.iibig.com/P1101.

About iiBIG
iiBIG (International Institute for Business Information & Growth) is an unbiased, independent company dedicated to organizing business-to-business conferences and seminars for senior-level business executives. For more information, visit: http://www.iibig.com.

Contact Information